But because we are at scale we don’t expect CapEx to substantially change, okay? We talked about an increase of interest expense. So maybe that goes up call it $50 million year-over-year, okay. But also we will save year-over-year over $60 million of cash distributions related to the APC unwound. So the net of the two is a positive call it, $10 million to $15 million. So — and the other thing is in terms of settling one of the other things you know about us is we’ve been very focused on kind of cleaning up legacy issues, okay? So back in 2019, we will — not only us, but the whole industry was facing substantial amount of liabilities and not a lot of clarity around it, okay? So as you know a couple of years ago we settled the Opana ER. So last year we had $130-some million payment related to that.
This year, we had an $86 million payment and there is only one payment of $50 million remaining in January of 2024. So 2024 versus 2023, right, it’s $30 million less of a headwind, regarding the Opana ER, right? So that’s going to be positive. And then after that, right, Opana is behind us. To step down the liabilities, we talked about opioids. Our team is working really hard. We’ve put a place holder a pretty well educated estimate of about $22 million in our balance sheet for that potential liability. It may be a little bit more, maybe a little less. And as you know usually those liabilities get settled over a long period of time on multiple years. So we don’t believe that’s going to be, have a material impact at any given year. So overall I think when you look at all of those pieces, I think there is more cash that stays in the company over the next few years and growing than in prior years.
Chintu Patel: Thank you, Tasos. And the International Balaji, we are two strategies we have. One is using Amneal’s own portfolio which is very huge on injectables and the retail side as well as in the future it could be biosimilars. We are partnering in Europe. We have Orion, 100 years old Finland Company as our partner. So we’re working through their sales channel to sell the product Amneal’s products. Middle East we just signed up multiple partnerships. So we’ll be selling Ennis product in Middle East and US FDA approved sites approved products obviously has more premium than the other products. We have finalized our term sheets on Southeast Asia as well and going now to South America Canada. So we’ll cover pretty much the entire world some parts of Africa as well.
And basically it would be an incremental revenue of Amneal’s products, which are sold in the United States. So that’s the first strategy which we expect to go to $50 million $100 million plus it will keep growing because we have more and more products that we are launching. And again, complex products in international markets are very good. We are not taking every product out there. It has to obviously make certain margins for us. And the second strategy is India strategy. That is a stand-alone strategy. That we are — we have direct marketing. We have spent quite a bit of time understanding the market and we have launched our sales forces in hospital several products including diagnostic in hospitals. And now we are just expanded ophthalmology the eye care products portfolio in India and we will be entering oncology and CNS as well.
So, pretty broad strategy because we believe India is growing at 14% 15% every year from a market and it has even more room to grow. So, we want to be part of that growth journey, and we have the science. We have the company’s reputation and set up in India. So, we believe India can become a substantial market. It’s very small today like $10 million will keep growing but it has – it can go pretty long way in India. So that’s the international strategy we have.
Anthony DiMeo: Just Balaji to add one thing in India. We are looking at beyond our current portfolio especially in a rare disease and some other unmet areas in India because there is a huge unmet needs on many, many products. So, we are looking at certain branded aspect of product development and launching India specifics and that looks pretty exciting in that space, because there is a lot more awareness affordability and people are talking about health and prevention than the previous time. And the India market is shaping up very differently than what we have seen before. So we want to be there and we want to be a value-added something that is unique and new.
Balaji Prasad: Thank you all.
Operator: Thank you, Balaji. We have no further questions registered today. So with that I will hand over to Chirag Patel for final remarks.
Chirag Patel: Well, thank you very much everybody and have a nice day.
Operator: This concludes today’s call. Thank you all for your participation. You may now disconnect your lines.
